Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 16, 2026

Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair

View original at finance.yahoo.com
Stock market today: Dow, S&P 500, Nasdaq steady as Trump wavers on Kevin Hassett as next Fed chair US stocks pared gains on Friday as uncertainty over the next Fed chair weighed on markets, while strong bank earnings and ongoing geopolitical tensions capped a volatile week…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Moving Hassett to Fed would mean losing him from current role

    80% confidence
  • Small-cap earnings are just beginning to take off after two-year earnings recession

    80% confidence
  • Affordability conditions taking toll on lower and mid-range housing sectors

    80% confidence
  • Lower interest rates help small caps as 40% of Russell 2000 debt is variable

    80% confidence
  • Trump wants to keep Kevin Hassett as NEC director rather than naming him Fed Chair

    80% confidence
  • Tehran's crackdown on protesters is easing

    80% confidence
  • Small caps can outperform for over a decade when they begin outperforming

    80% confidence
  • Fed sees risks to job market and should be ready to cut rates

    80% confidence
  • ASML shares could surge 70% in bull case

    80% confidence
  • May use tariffs in pursuit of Greenland acquisition

    80% confidence
  • Investors pondering what would push 10-year yields to 4.25% or 4.05%

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com